Browsing Tag
Remibrutinib
1 post
Novartis’ remibrutinib shows promising results in Phase III studies for chronic spontaneous urticaria
Novartis has revealed encouraging data from the Phase III REMIX-1 and REMIX-2 studies. The studies focused on remibrutinib,…